# PRECEDE

Source: https://onco.cc/trials/precede/  
OnCo record `precede` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PRECEDE is a very large international study following people whose genes or family history put them at high risk of pancreatic cancer, with yearly scans and stored blood samples, to find out how to catch the cancer early enough to cure it; it is still enrolling towards 20,000 participants.

## Summary

PRECEDE (the Pancreatic Cancer Early Detection Consortium) is a prospective observational cohort registered by Arbor Research Collaborative for Health and run across more than 40 academic centres. It enrols people at high risk of pancreatic ductal adenocarcinoma, including carriers of germline pathogenic variants, members of familial pancreatic cancer kindreds, people with pancreatic cysts and cohorts with new-onset diabetes, in defined cohorts with protocol-driven surveillance imaging and longitudinal biospecimen collection. The primary outcome is the development of pancreatic ductal adenocarcinoma; the consortium's stated aim is to raise five-year survival by detecting the disease at a curable stage.

The registry lists an estimated 20,000 participants with completion in 2030 and no results. With the older CAPS programme it defines high-risk surveillance on the corpus's pancreatic cancer page.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Also known as: Pancreatic Cancer Early Detection Consortium
- Tags: soc-trials
- Registry id: NCT04970056
- Phase: observational
- Setting: People at high risk of pancreatic cancer (germline pathogenic variants, familial pancreatic cancer kindreds, pancreatic cysts and new-onset diabetes cohorts) followed prospectively with imaging and biobanking across more than 40 centres, with the development of pancreatic ductal adenocarcinoma as the primary outcome
- Sponsor: Arbor Research Collaborative for Health
- Enrolled: 20000

## Sources

- ClinicalTrials.gov NCT04970056: https://clinicaltrials.gov/study/NCT04970056

## Connected records

- cancers: [Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors](https://onco.cc/cancers/ipmn-cystic-precursors/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [High-risk pancreatic surveillance (CAPS / PRECEDE)](https://onco.cc/technologies/pancreatic-surveillance/)
- key papers: [Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium](https://onco.cc/key-papers/paper-caps-consortium-surveillance-recommendations-gut-2020/), [Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium](https://onco.cc/key-papers/paper-worthington-precede-early-detection-biomarkers-ijc-2026/), [Recommendations for a more organized and effective approach to the early detection of pancreatic cancer from the PRECEDE (Pancreatic Cancer Early Detection) consortium](https://onco.cc/key-papers/paper-gonda-precede-consortium-recommendations-gastroenterology-2021/), [Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance](https://onco.cc/key-papers/paper-canto-caps-long-term-surveillance-gastroenterology-2018/), [The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival](https://onco.cc/key-papers/paper-dbouk-caps5-stage-survival-jco-2022/)
- terms: [CAPS: the Cancer of the Pancreas Screening consortium and its surveillance studies (CAPS1 to CAPS5)](https://onco.cc/terms/caps-consortium-pancreatic-screening/), [Familial pancreatic cancer and inherited risk (who qualifies for surveillance)](https://onco.cc/terms/familial-pancreatic-cancer/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- ideas: [Surveillance for every germline carrier found by universal testing, inside a registry rather than a research exception](https://onco.cc/ideas/idea-pdac-surveillance-for-every-germline-carrier/)

---
JSON: https://onco.cc/api/v1/entities/precede.json